161 related articles for article (PubMed ID: 12398786)
1. Antithrombin III in patients admitted to intensive care units: a multicenter observational study.
Messori A; Vacca F; Vaiani M; Trippoli S;
Crit Care; 2002 Oct; 6(5):447-51. PubMed ID: 12398786
[TBL] [Abstract][Full Text] [Related]
2. Impact of withdrawing antithrombin III administration from management of septic patients with or without disseminated intravascular coagulation.
Kawano S; Uchino S; Endo A; Saito K; Iwai K; Kase Y; Takinami M
Blood Coagul Fibrinolysis; 2014 Dec; 25(8):795-800. PubMed ID: 24806318
[TBL] [Abstract][Full Text] [Related]
3. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study.
Baudo F; Caimi TM; de Cataldo F; Ravizza A; Arlati S; Casella G; Carugo D; Palareti G; Legnani C; Ridolfi L; Rossi R; D'Angelo A; Crippa L; Giudici D; Gallioli G; Wolfler A; Calori G
Intensive Care Med; 1998 Apr; 24(4):336-42. PubMed ID: 9609411
[TBL] [Abstract][Full Text] [Related]
4. Antithrombin III in Sepsis. New evidences and open questions.
Ostermann H
Minerva Anestesiol; 2002 May; 68(5):445-8. PubMed ID: 12029261
[TBL] [Abstract][Full Text] [Related]
5. Use of gabexate mesylate in Italian hospitals: a multicentre observational study.
Pelagotti F; Cecchi M; Messori A;
J Clin Pharm Ther; 2003 Jun; 28(3):191-6. PubMed ID: 12795778
[TBL] [Abstract][Full Text] [Related]
6. The use of antithrombin III (ATIII) for disseminated intravascular coagulation (DIC) during septic shock.
Cohendy R; Lefrant JY; de la Coussaye JE
Intensive Care Med; 1998 Dec; 24(12):1344. PubMed ID: 9885894
[No Abstract] [Full Text] [Related]
7. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation.
Fourrier F; Chopin C; Huart JJ; Runge I; Caron C; Goudemand J
Chest; 1993 Sep; 104(3):882-8. PubMed ID: 8365305
[TBL] [Abstract][Full Text] [Related]
8. Effect of antithrombin III among patients with disseminated intravascular coagulation in obstetrics: a nationwide observational study in Japan.
Iwasaki Y; Ohbe H; Shigemi D; Fushimi K; Yasunaga H
BJOG; 2022 Apr; 129(5):805-811. PubMed ID: 34545675
[TBL] [Abstract][Full Text] [Related]
9. [Studies on antithrombin III. II. The role for antithrombin III (ATIII) in the control of disseminated intravascular coagulation (DIC). (The effect of the administration of ATIII concentrates in experimental DIC and in clinical DIC) (author's transl)].
Takahashi K
Nihon Ketsueki Gakkai Zasshi; 1980 Oct; 43(5):889-97. PubMed ID: 6940410
[No Abstract] [Full Text] [Related]
10. Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. The Antithrombin III Study Group.
Schwartz RS; Bauer KA; Rosenberg RD; Kavanaugh EJ; Davies DC; Bogdanoff DA
Am J Med; 1989 Sep; 87(3B):53S-60S. PubMed ID: 2679072
[TBL] [Abstract][Full Text] [Related]
11. [The effect of antithrombin iii concentrations during cardiopulmonary surgery].
Sonzogni V; Bellavita P; Carrara B; Cossolini M; Ferri F; Fabretti F; Mamprin F; Pelliccioli I
Minerva Anestesiol; 2000; 66(1-2):17-23. PubMed ID: 10736978
[TBL] [Abstract][Full Text] [Related]
12. Improvement in coagulation markers with antithrombin--beneficial in severe sepsis?
Wiedermann CJ
Crit Care Med; 2004 Sep; 32(9):1968-9. PubMed ID: 15343032
[No Abstract] [Full Text] [Related]
13. Effect of long-term and high-dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis.
Hoffmann JN; Mühlbayer D; Jochum M; Inthorn D
Crit Care Med; 2004 Sep; 32(9):1851-9. PubMed ID: 15343012
[TBL] [Abstract][Full Text] [Related]
14. [[Antithrombin III concentrates in the treatmetn of sepsis and septic shock: indictions, limits and future prospects] ].
Baudo F; de Cataldo F
Minerva Anestesiol; 2000 Nov; 66(11 Suppl 1):3-23. PubMed ID: 11213542
[TBL] [Abstract][Full Text] [Related]
15. The initial experience of antithrombin III in the management of neonates with necrotizing enterocolitis.
St Peter SD; Little DC; Calkins CM; Holcomb GW; Snyder CL; Ostlie DJ
J Pediatr Surg; 2007 Apr; 42(4):704-8. PubMed ID: 17448770
[TBL] [Abstract][Full Text] [Related]
16. [Are there certified indications for the use of antithrombin III in intensive care].
Kulka PJ; Tryba M; Lange S
Anasthesiol Intensivmed Notfallmed Schmerzther; 2001 Mar; 36(3):143-53. PubMed ID: 11324345
[TBL] [Abstract][Full Text] [Related]
17. Acquired antithrombin III deficiency: laboratory diagnosis, incidence, clinical implications, and treatment with antithrombin III concentrate.
Büller HR; ten Cate JW
Am J Med; 1989 Sep; 87(3B):44S-48S. PubMed ID: 2679070
[TBL] [Abstract][Full Text] [Related]
18. Activity-guided antithrombin III therapy in severe surgical sepsis: efficacy and safety according to a retrospective data analysis.
Moubarak P; Zilker S; Wolf H; Hofner B; Kneib T; Küchenhoff H; Jauch KW; Hartl WH
Shock; 2008 Dec; 30(6):634-41. PubMed ID: 18520701
[TBL] [Abstract][Full Text] [Related]
19. High dose of intravenous antithrombin III without heparin in the treatment of disseminated intravascular coagulation and organ failure in four children.
Fuse S; Tomita H; Yoshida M; Hori T; Igarashi C; Fujita S
Am J Hematol; 1996 Sep; 53(1):18-21. PubMed ID: 8813091
[TBL] [Abstract][Full Text] [Related]
20. Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023].
Rublee D; Opal SM; Schramm W; Keinecke HO; Knaub S
Crit Care; 2002 Aug; 6(4):349-56. PubMed ID: 12225612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
